Post-intravitreal anti-VEGF endophthalmitis in the United Kingdom: incidence, features, risk factors, and outcomes
- 12 October 2012
- journal article
- research article
- Published by Springer Nature in Eye
- Vol. 26 (12) , 1517-1526
- https://doi.org/10.1038/eye.2012.199
Abstract
Purpose Methods Results DiscussionKeywords
This publication has 48 references indexed in Scilit:
- Endophthalmitis after cataract surgery in China, 1995–2009Journal of Cataract & Refractive Surgery, 2011
- Prevention, diagnosis, and management of acute postoperative bacterial endophthalmitisJournal of Cataract & Refractive Surgery, 2011
- Evaluation of the Incidence of Endophthalmitis after Intravitreal Injection of Anti-Vascular Endothelial Growth FactorOphthalmologica, 2011
- Outcomes and Risk Factors Associated with Endophthalmitis after Intravitreal Injection of Anti-Vascular Endothelial Growth Factor AgentsOphthalmology, 2011
- Ocular Complications After Anti–Vascular Endothelial Growth Factor Therapy in Medicare Patients With Age-Related Macular DegenerationAmerican Journal of Ophthalmology, 2011
- A review of safety incidents in England and Wales for vascular endothelial growth factor inhibitor medicationsEye, 2011
- Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agentsBritish Journal of Ophthalmology, 2010
- INCIDENCE OF ENDOPHTHALMITIS RELATED TO INTRAVITREAL INJECTION OF BEVACIZUMAB AND RANIBIZUMABRetina, 2008
- INCIDENCE OF ACUTE ONSET ENDOPHTHALMITIS FOLLOWING INTRAVITREAL BEVACIZUMAB (AVASTIN) INJECTIONRetina, 2008
- Ranibizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006